Enzyme-Responsive Liposomes for the Delivery of Anticancer Drugs

Bioconjugate Chemistry

Volumn 28, Issue 4, 2017, Pages 857-868

  Fouladi, Farnaz ^a   Steffen, Kristine J ^a   Mallik, Sanku ^a  

^a NORTH DAKOTA STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CONTROLLED DRUG DELIVERY; ENZYMES; HISTOLOGY; LIGANDS; LIPID BILAYERS; TARGETED DRUG DELIVERY; TISSUE;

ANTICANCER DRUG; DRUG CONCENTRATION; HEALTHY TISSUES; NANOCARRIERS; STIMULI-RESPONSIVE; TARGET SITES; TARGET TISSUES; TARGETING LIGANDS; THERAPEUTIC DRUGS; TOXIC EFFECT;

LIPOSOMES;

ANTINEOPLASTIC AGENT; CATHEPSIN B; ELASTASE; ENZYME RESPONSIVE LIPOSOME; LIPOPEPTIDE; LIPOSOME; MATRIX METALLOPROTEINASE; PHOSPHOLIPASE A2; PHOSPHOLIPID; POLYMER; PRODRUG; PROSTATE SPECIFIC ANTIGEN; UNCLASSIFIED DRUG; UROKINASE; DELAYED RELEASE FORMULATION; PANCREATIC ELASTASE; SECRETORY PHOSPHOLIPASE A2;

ARTICLE; CYTOTOXICITY; DRUG DELIVERY SYSTEM; ENZYME ACTIVITY; HUMAN; LIPID BILAYER; LIPID MEMBRANE; NONHUMAN; SURFACE PROPERTY; ANIMAL; BIOCATALYSIS; CHEMISTRY; DELAYED RELEASE FORMULATION; METABOLISM; NEOPLASMS; PROCEDURES;

ANIMALS; ANTINEOPLASTIC AGENTS; BIOCATALYSIS; CATHEPSIN B; DELAYED-ACTION PREPARATIONS; DRUG DELIVERY SYSTEMS; HUMANS; LIPOPEPTIDES; LIPOSOMES; MATRIX METALLOPROTEINASES; NEOPLASMS; PANCREATIC ELASTASE; PHOSPHOLIPASES A2, SECRETORY; POLYMERS; PRODRUGS; PROSTATE-SPECIFIC ANTIGEN; UROKINASE-TYPE PLASMINOGEN ACTIVATOR;

EID: 85018484786     PISSN: 10431802     EISSN: 15204812     Source Type: Journal    
DOI: 10.1021/acs.bioconjchem.6b00736     Document Type: Article

References (124)

1. Kumari, P., Ghosh, B., and Biswas, S. (2016) Nanocarriers for cancer-targeted drug delivery J. Drug Target 24, 179-191 10.3109/1061186X.2015.1051049
2. Anajafi, T. and Mallik, S. (2015) Polymersome-based drug-delivery strategies for cancer therapeutics Ther. Delivery 6, 521-534 10.4155/tde.14.125
3. Immordino, M. L., Dosio, F., and Cattel, L. (2006) Stealth liposomes: review of the basic science, rationale, and clinical applications, existing and potential Int. J. Nanomedicine 1, 297-315
4. Deshpande, P. P., Biswas, S., and Torchilin, V. P. (2013) Current trends in the use of liposomes for tumor targeting Nanomedicine (London, U. K.) 8, 1509-1528 10.2217/nnm.13.118
5. Kraft, J. C., Freeling, J. P., Wang, Z., and Ho, R. J. (2014) Emerging research and clinical development trends of liposome and lipid nanoparticle drug delivery systems J. Pharm. Sci. 103, 29-52 10.1002/jps.23773
6. Mallick, S. and Choi, J. S. (2014) Liposomes: versatile and biocompatible nanovesicles for efficient biomolecules delivery J. Nanosci. Nanotechnol. 14, 755-765 10.1166/jnn.2014.9080
7. Allen, T. M. and Cleland, L. G. (1980) Serum-induced leakage of liposome contents Biochim. Biophys. Acta, Biomembr. 597, 418-426 10.1016/0005-2736(80)90118-2
8. Ishida, T., Harashima, H., and Kiwada, H. (2002) Liposome clearance Biosci. Rep. 22, 197-224 10.1023/A:1020134521778
9. Klibanov, A. L., Maruyama, K., Torchilin, V. P., and Huang, L. (1990) Amphipathic polyethyleneglycols effectively prolong the circulation time of liposomes FEBS Lett. 268, 235-237 10.1016/0014-5793(90)81016-H
10. Blume, G. and Cevc, G. (1990) Liposomes for the sustained drug release in vivo Biochim. Biophys. Acta, Biomembr. 1029, 91-97 10.1016/0005-2736(90)90440-Y
11. Allen, T. M., Hansen, C., Martin, F., Redemann, C., and Yau-Young, A. (1991) Liposomes containing synthetic lipid derivatives of poly(ethylene glycol) show prolonged circulation half-lives in vivo Biochim. Biophys. Acta, Biomembr. 1066, 29-36 10.1016/0005-2736(91)90246-5
12. Maruyama, K., Yuda, T., Okamoto, A., Ishikura, C., Kojima, S., and Iwatsuru, M. (1991) Effect of molecular weight in amphipathic polyethyleneglycol on prolonging the circulation time of large unilamellar liposomes Chem. Pharm. Bull. 39, 1620-1622 10.1248/cpb.39.1620
13. Senior, J., Delgado, C., Fisher, D., Tilcock, C., and Gregoriadis, G. (1991) Influence of surface hydrophilicity of liposomes on their interaction with plasma protein and clearance from the circulation: studies with poly(ethylene glycol)-coated vesicles Biochim. Biophys. Acta, Biomembr. 1062, 77-82 10.1016/0005-2736(91)90337-8
14. Papahadjopoulos, D., Allen, T. M., Gabizon, A., Mayhew, E., Matthay, K., Huang, S. K., Lee, K. D., Woodle, M. C., Lasic, D. D., and Redemann, C. (1991) Sterically stabilized liposomes: improvements in pharmacokinetics and antitumor therapeutic efficacy Proc. Natl. Acad. Sci. U. S. A. 88, 11460-11464 10.1073/pnas.88.24.11460
15. Allen, T. M. (1994) The use of glycolipids and hydrophilic polymers in avoiding rapid uptake of liposomes by the mononuclear phagocyte system. Adv. Drug Delivery Rev. 13, 285-309 10.1016/0169-409X(94)90016-7
16. Barenholz, Y. (2012) Doxil®-The first FDA-approved nano-drug: Lessons learned J. Controlled Release 160, 117-134 10.1016/j.jconrel.2012.03.020
17. Fang, J., Nakamura, H., and Maeda, H. (2011) The EPR effect: Unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect Adv. Drug Delivery Rev. 63, 136-151 10.1016/j.addr.2010.04.009
18. Torchilin, V. (2011) Tumor delivery of macromolecular drugs based on the EPR effect Adv. Drug Delivery Rev. 63, 131-135 10.1016/j.addr.2010.03.011
19. Sapra, P. and Allen, T. M. (2003) Ligand-targeted liposomal anticancer drugs Prog. Lipid Res. 42, 439-462 10.1016/S0163-7827(03)00032-8
20. Greish, K. (2007) Enhanced permeability and retention of macromolecular drugs in solid tumors: a royal gate for targeted anticancer nanomedicines J. Drug Target 15, 457-464 10.1080/10611860701539584
21. Allen, T. M. and Cullis, P. R. (2013) Liposomal drug delivery systems: from concept to clinical applications Adv. Drug Delivery Rev. 65, 36-48 10.1016/j.addr.2012.09.037
22. Lopes de Menezes, D. E., Pilarski, L. M., and Allen, T. M. (1998) In vitro and in vivo targeting of immunoliposomal doxorubicin to human B-cell lymphoma Cancer Res. 58, 3320-3330
23. Park, J. W., Hong, K., Kirpotin, D. B., Colbern, G., Shalaby, R., Baselga, J., Shao, Y., Nielsen, U. B., Marks, J. D., and Moore, D. et al. 2002, Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery Clin. Cancer Res. 8, 1172-1181
24. Vingerhoeds, M. H., Steerenberg, P. A., Hendriks, J. J., Dekker, L. C., Van Hoesel, Q. G., Crommelin, D. J., and Storm, G. (1996) Immunoliposome-mediated targeting of doxorubicin to human ovarian carcinoma in vitro and in vivo Br. J. Cancer 74, 1023-1029 10.1038/bjc.1996.484
25. Karanth, H. and Murthy, R. S. (2007) pH-sensitive liposomes - principle and application in cancer therapy J. Pharm. Pharmacol. 59, 469-483 10.1211/jpp.59.4.0001
26. Needham, D., Anyarambhatla, G., Kong, G., and Dewhirst, M. W. (2000) A new temperature-sensitive liposome for use with mild hyperthermia: characterization and testing in a human tumor xenograft model Cancer Res. 60, 1197-1201
27. Wan, Y., Angleson, J. K., and Kutateladze, A. G. (2002) Liposomes from novel photolabile phospholipids: light-induced unloading of small molecules as monitored by PFG NMR J. Am. Chem. Soc. 124, 5610-5611 10.1021/ja016874i
28. Schroeder, A., Honen, R., Turjeman, K., Gabizon, A., Kost, J., and Barenholz, Y. (2009) Ultrasound triggered release of cisplatin from liposomes in murine tumors J. Controlled Release 137, 63-68 10.1016/j.jconrel.2009.03.007
29. Zhu, L., Huo, Z., Wang, L., Tong, X., Xiao, Y., and Ni, K. (2009) Targeted delivery of methotrexate to skeletal muscular tissue by thermosensitive magnetoliposomes Int. J. Pharm. 370, 136-143 10.1016/j.ijpharm.2008.12.003
30. Bibi, S., Lattmann, E., Mohammed, A. R., and Perrie, Y. (2012) Trigger release liposome systems: local and remote controlled delivery J. Microencapsulation 29, 262-276 10.3109/02652048.2011.646330
31. Movahedi, F., Hu, R. G., Becker, D. L., and Xu, C. (2015) Stimuli-responsive liposomes for the delivery of nucleic acid therapeutics Nanomedicine 11, 1575-1584 10.1016/j.nano.2015.03.006
32. de la Rica, R., Aili, D., and Stevens, M. M. (2012) Enzyme-responsive nanoparticles for drug release and diagnostics Adv. Drug Delivery Rev. 64, 967-978 10.1016/j.addr.2012.01.002
33. Dennis, E. A., Cao, J., Hsu, Y.-H., Magrioti, V., and Kokotos, G. (2011) Phospholipase A(2) Enzymes: Physical Structure, Biological Function, Disease Implication, Chemical Inhibition, and Therapeutic Intervention Chem. Rev. 111, 6130-6185 10.1021/cr200085w
34. Graff, J. R., Konicek, B. W., Deddens, J. A., Chedid, M., Hurst, B. M., Colligan, B., Neubauer, B. L., Carter, H. W., and Carter, J. H. (2001) Expression of group IIa secretory phospholipase A2 increases with prostate tumor grade Clin. Cancer Res. 7, 3857-3861
35. Pruzanski, W. and Vadas, P. (1988) Secretory synovial fluid phospholipase A2 and its role in the pathogenesis of inflammation in arthritis J. Rheumatol 15, 1601-1603
36. Rosengren, B., Jonsson-Rylander, A. C., Peilot, H., Camejo, G., and Hurt-Camejo, E. (2006) Distinctiveness of secretory phospholipase A2 group IIA and V suggesting unique roles in atherosclerosis Biochim. Biophys. Acta, Mol. Cell Biol. Lipids 1761, 1301-1308 10.1016/j.bbalip.2006.06.008
37. Leistad, L., Feuerherm, A. J., Ostensen, M., Faxvaag, A., and Johansen, B. (2004) Presence of secretory group IIa and V phospholipase A2 and cytosolic group IValpha phospholipase A2 in chondrocytes from patients with rheumatoid arthritis Clin. Chem. Lab. Med. 42, 602-610 10.1515/CCLM.2004.104
38. Yamashita, S., Yamashita, J., and Ogawa, M. (1994) Overexpression of group II phospholipase A2 in human breast cancer tissues is closely associated with their malignant potency Br. J. Cancer 69, 1166-1170 10.1038/bjc.1994.229
39. Kiyohara, H., Egami, H., Kako, H., Shibata, Y., Murata, K., Ohshima, S., Sei, K., Suko, S., Kurano, R., and Ogawa, M. (1993) Immunohistochemical localization of group II phospholipase A2 in human pancreatic carcinomas Int. J. Pancreatol 13, 49-57
40. Dong, Q., Patel, M., Scott, K. F., Graham, G. G., Russell, P. J., and Sved, P. (2006) Oncogenic action of phospholipase A2 in prostate cancer Cancer Lett. 240, 9-16 10.1016/j.canlet.2005.08.012
41. Yamashita, S., Yamashita, J., Sakamoto, K., Inada, K., Nakashima, Y., Murata, K., Saishoji, T., Nomura, K., and Ogawa, M. (1993) Increased expression of membrane-associated phospholipase A2 shows malignant potential of human breast cancer cells Cancer 71, 3058-3064 10.1002/1097-0142(19930515)71:10<3058::AID-CNCR2820711028>3.0.CO;2-8
42. Jiang, J., Neubauer, B. L., Graff, J. R., Chedid, M., Thomas, J. E., Roehm, N. W., Zhang, S., Eckert, G. J., Koch, M. O., and Eble, J. N. et al. 2002, Expression of Group IIA Secretory Phospholipase A2 Is Elevated in Prostatic Intraepithelial Neoplasia and Adenocarcinoma Am. J. Pathol. 160, 667-671 10.1016/S0002-9440(10)64886-9
43. Sved, P., Scott, K. F., McLeod, D., King, N. J., Singh, J., Tsatralis, T., Nikolov, B., Boulas, J., Nallan, L., and Gelb, M. H. (2004) Oncogenic action of secreted phospholipase A2 in prostate cancer Cancer Res. 64, 6934-6940 10.1158/0008-5472.CAN-03-3018
44. Mock, J. N., Costyn, L. J., Wilding, S. L., Arnold, R. D., and Cummings, B. S. (2013) Evidence for distinct mechanisms of uptake and antitumor activity of secretory phospholipase A2 responsive liposome in prostate cancer Integr Biol. (Camb) 5, 172-182 10.1039/C2IB20108A
45. Sitkiewicz, I., Stockbauer, K. E., and Musser, J. M. (2007) Secreted bacterial phospholipase A2 enzymes: better living through phospholipolysis Trends Microbiol. 15, 63-69 10.1016/j.tim.2006.12.003
46. Thamphiwatana, S., Gao, W., Pornpattananangkul, D., Zhang, Q., Fu, V., Li, J., Obonyo, M., Zhang, L., and Li, J. (2014) Phospholipase A2-responsive antibiotic delivery via nanoparticle-stabilized liposomes for the treatment of bacterial infection J. Mater. Chem. B 2, 8201-8207 10.1039/C4TB01110D
47. Cummings, B. S., McHowat, J., and Schnellmann, R. G. (2000) Phospholipase A(2)s in cell injury and death J. Pharmacol Exp Ther 294, 793-799
48. Lambeau, G. and Gelb, M. H. (2008) Biochemistry and physiology of mammalian secreted phospholipases A2 Annu. Rev. Biochem. 77, 495-520 10.1146/annurev.biochem.76.062405.154007
49. Six, D. A. and Dennis, E. A. (2000) The expanding superfamily of phospholipase A(2) enzymes: classification and characterization Biochim. Biophys. Acta, Mol. Cell Biol. Lipids 1488, 1-19 10.1016/S1388-1981(00)00105-0
50. Zhu, G., Mock, J. N., Aljuffali, I., Cummings, B. S., and Arnold, R. D. (2011) Secretory Phospholipase A(2) Responsive Liposomes J. Pharm. Sci. 100, 3146-3159 10.1002/jps.22530
51. Leidy, C., Linderoth, L., Andresen, T. L., Mouritsen, O. G., Jorgensen, K., and Peters, G. H. (2006) Domain-induced activation of human phospholipase A2 type IIA: local versus global lipid composition Biophys. J. 90, 3165-3175 10.1529/biophysj.105.070987
52. Jorgensen, K., Davidsen, J., and Mouritsen, O. G. (2002) Biophysical mechanisms of phospholipase A2 activation and their use in liposome-based drug delivery FEBS Lett. 531, 23-27 10.1016/S0014-5793(02)03408-7
53. Halperin, A. and Mouritsen, O. G. (2005) Role of lipid protrusions in the function of interfacial enzymes Eur. Biophys. J. 34, 967-971 10.1007/s00249-005-0466-z
54. Honger, T., Jorgensen, K., Biltonen, R. L., and Mouritsen, O. G. (1996) Systematic relationship between phospholipase A2 activity and dynamic lipid bilayer microheterogeneity Biochemistry 35, 9003-9006 10.1021/bi960866a
55. Hoyrup, P., Callisen, T. H., Jensen, M. O., Halperin, A., and Mouritsen, O. G. (2004) Lipid protrusions, membrane softness, and enzymatic activity Phys. Chem. Chem. Phys. 6, 1608-1615 10.1039/B314146B
56. Honger, T., Jorgensen, K., Stokes, D., Biltonen, R. L., and Mouritsen, O. G. (1997) Phospholipase A2 activity and physical properties of lipid-bilayer substrates Methods Enzymol. 286, 168-190 10.1016/S0076-6879(97)86011-9
57. Vermehren, C., Kiebler, T., Hylander, I., Callisen, T. H., and Jorgensen, K. (1998) Increase in phospholipase A2 activity towards lipopolymer-containing liposomes Biochim. Biophys. Acta, Biomembr. 1373, 27-36 10.1016/S0005-2736(98)00084-4
58. Jorgensen, K., Vermehren, C., and Mouritsen, O. G. (1999) Enhancement of phospholipase A2 catalyzed degradation of polymer grafted PEG-liposomes: effects of lipopolymer-concentration and chain-length Pharm. Res. 16, 1491-1493 10.1023/A:1018931915924
59. Davidsen, J., Jørgensen, K., Andresen, T. L., and Mouritsen, O. G. (2003) Secreted phospholipase A2 as a new enzymatic trigger mechanism for localised liposomal drug release and absorption in diseased tissue Biochim. Biophys. Acta, Biomembr. 1609, 95-101 10.1016/S0005-2736(02)00659-4
60. Davidsen, J., Vermehren, C., Frokjaer, S., Mouritsen, O. G., and Jørgensen, K. (2001) Drug delivery by phospholipase A2 degradable liposomes Int. J. Pharm. 214, 67-69 10.1016/S0378-5173(00)00634-7
61. Quach, N. D., Mock, J. N., Scholpa, N. E., Eggert, M. W., Payre, C., Lambeau, G., Arnold, R. D., and Cummings, B. S. (2014) Role of the phospholipase A2 receptor in liposome drug delivery in prostate cancer cells Mol. Pharmaceutics 11, 3443-3451 10.1021/mp500174p
62. Hanasaki, K. (2004) Mammalian phospholipase A2: phospholipase A2 receptor. Biol. Pharm. Bull. 27, 1165-1167 10.1248/bpb.27.1165
63. Bernard, D. and Vindrieux, D. (2014) PLA2R1: expression and function in cancer Biochim. Biophys. Acta, Rev. Cancer 1846, 40-44 10.1016/j.bbcan.2014.03.003
64. Davidsen, J., Mouritsen, O. G., and Jorgensen, K. (2002) Synergistic permeability enhancing effect of lysophospholipids and fatty acids on lipid membranes Biochim. Biophys. Acta, Biomembr. 1564, 256-262 10.1016/S0005-2736(02)00461-3
65. Mouritsen, O. G., Andresen, T. L., Halperin, A., Hansen, P. L., Jakobsen, A. F., Jensen, U. B., Jensen, M. O., Jorgensen, K., Kaasgaard, T., and Leidy, C. (2006) Activation of interfacial enzymes at membrane surfaces J. Phys.: Condens. Matter 18, S1293-1304 10.1088/0953-8984/18/28/S12
66. Arouri, A. and Mouritsen, O. G. (2011) Phospholipase A(2)-susceptible liposomes of anticancer double lipid-prodrugs Eur. J. Pharm. Sci. 45, 408-420
67. Arouri, A. and Mouritsen, O. G. (2011) Anticancer double lipid prodrugs: liposomal preparation and characterization J. Liposome Res. 21, 296-305 10.3109/08982104.2011.563365
68. Pedersen, P. J., Christensen, M. S., Ruysschaert, T., Linderoth, L., Andresen, T. L., Melander, F., Mouritsen, O. G., Madsen, R., and Clausen, M. H. (2009) Synthesis and biophysical characterization of chlorambucil anticancer ether lipid prodrugs J. Med. Chem. 52, 3408-3415 10.1021/jm900091h
69. Pedersen, P. J., Adolph, S. K., Andresen, T. L., Madsen, M. W., Madsen, R., and Clausen, M. H. (2010) Prostaglandin phospholipid conjugates with unusual biophysical and cytotoxic properties Bioorg. Med. Chem. Lett. 20, 4456-4458
70. Pedersen, P. J., Adolph, S. K., Subramanian, A. K., Arouri, A., Andresen, T. L., Mouritsen, O. G., Madsen, R., Madsen, M. W., Peters, G. H., and Clausen, M. H. (2010) Liposomal formulation of retinoids designed for enzyme triggered release J. Med. Chem. 53, 3782-3792 10.1021/jm100190c
71. Lund, B. W., Piu, F., Gauthier, N. K., Eeg, A., Currier, E., Sherbukhin, V., Brann, M. R., Hacksell, U., and Olsson, R. (2005) Discovery of a potent, orally available, and isoform-selective retinoic acid beta2 receptor agonist J. Med. Chem. 48, 7517-7519 10.1021/jm050891r
72. Lund, B. W., Knapp, A. E., Piu, F., Gauthier, N. K., Begtrup, M., Hacksell, U., and Olsson, R. (2009) Design, synthesis, and structure-activity analysis of isoform-selective retinoic acid receptor beta ligands J. Med. Chem. 52, 1540-1545 10.1021/jm801532e
73. Berkovic, D. (1998) Cytotoxic etherphospholipid analogues Gen. Pharmacol. 31, 511-517 10.1016/S0306-3623(98)00081-0
74. Andresen, T. L., Jensen, S. S., Madsen, R., and Jorgensen, K. (2005) Synthesis and biological activity of anticancer ether lipids that are specifically released by phospholipase A2 in tumor tissue J. Med. Chem. 48, 7305-7314 10.1021/jm049006f
75. Jensen, S. S., Andresen, T. L., Davidsen, J., Hoyrup, P., Shnyder, S. D., Bibby, M. C., Gill, J. H., and Jorgensen, K. (2004) Secretory phospholipase A2 as a tumor-specific trigger for targeted delivery of a novel class of liposomal prodrug anticancer etherlipids Mol. Cancer Ther. 3, 1451-1458
76. Andresen, T. L., Davidsen, J., Begtrup, M., Mouritsen, O. G., and Jorgensen, K. (2004) Enzymatic release of antitumor ether lipids by specific phospholipase A2 activation of liposome-forming prodrugs J. Med. Chem. 47, 1694-1703 10.1021/jm031029r
77. Verma, R. P. and Hansch, C. (2007) Matrix metalloproteinases (MMPs): chemical-biological functions and (Q)SARs Bioorg. Med. Chem. 15, 2223-2268 10.1016/j.bmc.2007.01.011
78. Yan, C. and Boyd, D. D. (2007) Regulation of matrix metalloproteinase gene expression J. Cell. Physiol. 211, 19-26 10.1002/jcp.20948
79. Stetler-Stevenson, W. G., Aznavoorian, S., and Liotta, L. A. (1993) Tumor cell interactions with the extracellular matrix during invasion and metastasis Annu. Rev. Cell Biol. 9, 541-573 10.1146/annurev.cb.09.110193.002545
80. Chambers, A. F. and Matrisian, L. M. (1997) Changing views of the role of matrix metalloproteinases in metastasis J. Natl. Cancer Inst 89, 1260-1270 10.1093/jnci/89.17.1260
81. Curran, S. and Murray, G. I. (1999) Matrix metalloproteinases in tumour invasion and metastasis J. Pathol 189, 300-308
82. La Rocca, G., Pucci-Minafra, I., Marrazzo, A., Taormina, P., and Minafra, S. (2004) Zymographic detection and clinical correlations of MMP-2 and MMP-9 in breast cancer sera Br. J. Cancer 90, 1414-1421 10.1038/sj.bjc.6601725
83. Mook, O. R., Frederiks, W. M., and Van Noorden, C. J. (2004) The role of gelatinases in colorectal cancer progression and metastasis Biochim. Biophys. Acta, Rev. Cancer 1705, 69-89 10.1016/j.bbcan.2004.09.006
84. Keleg, S., Büchler, P., Ludwig, R., Büchler, M. W., and Friess, H. (2003) Invasion and metastasis in pancreatic cancer Mol. Cancer 2, 14-14 10.1186/1476-4598-2-14
85. Osinsky, S. P., Ganusevich, L. N., Bubnovskaya, N. V., Valkovskaya, A. V., Kovelskaya, T. K., and Zimina, S. V. (2005) Hypoxia level and matrix metalloproteinases-2 and -9 activity in Lewis lung carcinoma: correlation with metastasis Exp Oncol 27, 202-205
86. Zhu, L., Kate, P., and Torchilin, V. P. (2012) Matrix metalloprotease 2-responsive multifunctional liposomal nanocarrier for enhanced tumor targeting ACS Nano 6, 3491-3498 10.1021/nn300524f
87. Terada, T., Iwai, M., Kawakami, S., Yamashita, F., and Hashida, M. (2006) Novel PEG-matrix metalloproteinase-2 cleavable peptide-lipid containing galactosylated liposomes for hepatocellular carcinoma-selective targeting J. Controlled Release 111, 333-342 10.1016/j.jconrel.2005.12.023
88. Elegbede, A. I., Banerjee, J., Hanson, A. J., Tobwala, S., Ganguli, B., Wang, R., Lu, X., Srivastava, D. K., and Mallik, S. (2008) Mechanistic studies of the triggered release of liposomal contents by matrix metalloproteinase-9 J. Am. Chem. Soc. 130, 10633-10642 10.1021/ja801548g
89. Sarkar, N., Banerjee, J., Hanson, A. J., Elegbede, A. I., Rosendahl, T., Krueger, A. B., Banerjee, A. L., Tobwala, S., Wang, R., and Lu, X. et al. 2008, Matrix metalloproteinase-assisted triggered release of liposomal contents Bioconjugate Chem. 19, 57-64 10.1021/bc070081p
90. Sarkar, N. R., Rosendahl, T., Krueger, A. B., Banerjee, A. L., Benton, K., Mallik, S., and Srivastava, D. K. (2005) "Uncorking" of liposomes by matrix metalloproteinase-9 Chem. Commun. (Cambridge, U. K.) 999-1001 10.1039/B416827E
91. Banerjee, J., Hanson, A. J., Gadam, B., Elegbede, A. I., Tobwala, S., Ganguly, B., Wagh, A. V., Muhonen, W. W., Law, B., and Shabb, J. B. et al. 2009, Release of liposomal contents by cell-secreted matrix metalloproteinase-9 Bioconjugate Chem. 20, 1332-1339 10.1021/bc9000646
92. Liu, S., Bugge, T. H., and Leppla, S. H. (2001) Targeting of tumor cells by cell surface urokinase plasminogen activator-dependent anthrax toxin J. Biol. Chem. 276, 17976-17984 10.1074/jbc.M011085200
93. Duffy, M. J. (2002) Urokinase-type plasminogen activator: a potent marker of metastatic potential in human cancers Biochem. Soc. Trans. 30, 207-210 10.1042/bst0300207
94. Basel, M. T., Shrestha, T. B., Troyer, D. L., and Bossmann, S. H. (2011) Protease-sensitive, polymer-caged liposomes: a method for making highly targeted liposomes using triggered release ACS Nano 5, 2162-2175 10.1021/nn103362n
95. Doring, G. (1994) The role of neutrophil elastase in chronic inflammation Am. J. Respir. Crit. Care Med. 150, S114-117 10.1164/ajrccm/150.6-Pt-2.S114
96. Al-Haik, N., Lewis, D. A., and Struthers, G. (1984) Neutral protease, collagenase and elastase activities in synovial fluids from arthritic patients Agents Actions 15, 436-442 10.1007/BF01972384
97. Kawabata, K., Hagio, T., and Matsuoka, S. (2002) The role of neutrophil elastase in acute lung injury Eur. J. Pharmacol. 451, 1-10
98. Cantin, A. M., Hartl, D., Konstan, M. W., and Chmiel, J. F. (2015) Inflammation in cystic fibrosis lung disease: Pathogenesis and therapy J. Cystic Fibrosis 14, 419 10.1016/j.jcf.2015.03.003
99. Sato, T., Takahashi, S., Mizumoto, T., Harao, M., Akizuki, M., Takasugi, M., Fukutomi, T., and Yamashita, J. (2006) Neutrophil elastase and cancer Surg Oncol 15, 217-222 10.1016/j.suronc.2007.01.003
100. Moroy, G., Alix, A. J. P., Sapi, J., Hornebeck, W., and Bourguet, E. (2012) Neutrophil elastase as a target in lung cancer Anti-Cancer Agents Med. Chem. 12, 565-579 10.2174/187152012800617696
101. Yamashita, J., Ogawa, M., and Shirakusa, T. (1995) Free-form neutrophil elastase is an independent marker predicting recurrence in primary breast cancer J. Leukoc Biol. 57, 375-378
102. Starcher, B., O'Neal, P., Granstein, R. D., and Beissert, S. (1996) Inhibition of neutrophil elastase suppresses the development of skin tumors in hairless mice J. Invest. Dermatol. 107, 159-163 10.1111/1523-1747.ep12329559
103. Pak, C. C., Ali, S., Janoff, A. S., and Meers, P. (1998) Triggerable liposomal fusion by enzyme cleavage of a novel peptide-lipid conjugate Biochim. Biophys. Acta, Biomembr. 1372, 13-27 10.1016/S0005-2736(98)00041-8
104. Pak, C. C., Erukulla, R. K., Ahl, P. L., Janoff, A. S., and Meers, P. (1999) Elastase activated liposomal delivery to nucleated cells Biochim. Biophys. Acta, Biomembr. 1419, 111-126 10.1016/S0005-2736(98)00256-9
105. Denmeade, S. R., Sokoll, L. J., Chan, D. W., Khan, S. R., and Isaacs, J. T. (2001) Concentration of enzymatically active prostate-specific antigen (PSA) in the extracellular fluid of primary human prostate cancers and human prostate cancer xenograft models Prostate 48, 1-6 10.1002/pros.1075
106. Basu, H. S. and Frydman, B. (2002) Prostate-specific antigen: a diagnostic marker and a tool for targeted delivery of drugs to prostate tumors Expert Opin. Ther. Pat. 12, 1035-1046 10.1517/13543776.12.7.1035
107. Chandran, S. S., Nan, A., Rosen, D. M., Ghandehari, H., and Denmeade, S. R. (2007) A prostate-specific antigen activated N-(2-hydroxypropyl) methacrylamide copolymer prodrug as dual-targeted therapy for prostate cancer Mol. Cancer Ther. 6, 2928-2937 10.1158/1535-7163.MCT-07-0392
108. Denmeade, S. R., Jakobsen, C. M., Janssen, S., Khan, S. R., Garrett, E. S., Lilja, H., Christensen, S. B., and Isaacs, J. T. (2003) Prostate-specific antigen-activated thapsigargin prodrug as targeted therapy for prostate cancer J. Natl. Cancer Inst 95, 990-1000 10.1093/jnci/95.13.990
109. Denmeade, S. R., Nagy, A., Gao, J., Lilja, H., Schally, A. V., and Isaacs, J. T. (1998) Enzymatic activation of a doxorubicin-peptide prodrug by prostate-specific antigen Cancer Res. 58, 2537-2540
110. Khan, S. R. and Denmeade, S. R. (2000) In vivo activity of a PSA-activated doxorubicin prodrug against PSA-producing human prostate cancer xenografts Prostate 45, 80-83
111. Xiang, B., Dong, D.-W., Shi, N.-Q., Gao, W., Yang, Z.-Z., Cui, Y., Cao, D.-Y., and Qi, X.-R. (2013) PSA-responsive and PSMA-mediated multifunctional liposomes for targeted therapy of prostate cancer Biomaterials 34, 6976-6991 10.1016/j.biomaterials.2013.05.055
112. Wender, P. A., Mitchell, D. J., Pattabiraman, K., Pelkey, E. T., Steinman, L., and Rothbard, J. B. (2000) The design, synthesis, and evaluation of molecules that enable or enhance cellular uptake: Peptoid molecular transporters Proc. Natl. Acad. Sci. U. S. A. 97, 13003-13008 10.1073/pnas.97.24.13003
113. Perner, S., Hofer, M. D., Kim, R., Shah, R. B., Li, H., Moller, P., Hautmann, R. E., Gschwend, J. E., Kuefer, R., and Rubin, M. A. (2007) Prostate-specific membrane antigen expression as a predictor of prostate cancer progression Hum. Pathol. 38, 696-701 10.1016/j.humpath.2006.11.012
114. Gondi, C. S. and Rao, J. S. (2013) Cathepsin B as a cancer target Expert Opin. Ther. Targets 17, 281-291 10.1517/14728222.2013.740461
115. Hafez, I. M. and Cullis, P. R. (2001) Roles of lipid polymorphism in intracellular delivery Adv. Drug Delivery Rev. 47, 139-148 10.1016/S0169-409X(01)00103-X
116. Romberg, B., Flesch, F. M., Hennink, W. E., and Storm, G. (2008) Enzyme-induced shedding of a poly(amino acid)-coating triggers contents release from dioleoyl phosphatidylethanolamine liposomes Int. J. Pharm. 355, 108-113 10.1016/j.ijpharm.2007.11.055
117. Metselaar, J. M., Bruin, P., de Boer, L. W., de Vringer, T., Snel, C., Oussoren, C., Wauben, M. H., Crommelin, D. J., Storm, G., and Hennink, W. E. (2003) A novel family of L-amino acid-based biodegradable polymer-lipid conjugates for the development of long-circulating liposomes with effective drug-targeting capacity Bioconjugate Chem. 14, 1156-1164 10.1021/bc0340363
118. Liu, X. and Huang, G. (2013) Formation strategies, mechanism of intracellular delivery and potential clinical applications of pH-sensitive liposomes Asian J. Pharm. Sci. 8, 319-328 10.1016/j.ajps.2013.11.002
119. Ellens, H., Bentz, J., and Szoka, F. C. (1984) pH-induced destabilization of phosphatidylethanolamine-containing liposomes: role of bilayer contact Biochemistry 23, 1532-1538 10.1021/bi00302a029
120. Simoes, S., Moreira, J. N., Fonseca, C., Duzgunes, N., and de Lima, M. C. (2004) On the formulation of pH-sensitive liposomes with long circulation times Adv. Drug Deliv Rev. 56, 947-965
121. Zhang, J. X., Zalipsky, S., Mullah, N., Pechar, M., and Allen, T. M. (2004) Pharmaco attributes of dioleoylphosphatidylethanolamine/cholesterylhemisuccinate liposomes containing different types of cleavable lipopolymers Pharmacol. Res. 49, 185-198 10.1016/j.phrs.2003.09.003
122. Kirpotin, D., Hong, K., Mullah, N., Papahadjopoulos, D., and Zalipsky, S. (1996) Liposomes with detachable polymer coating: destabilization and fusion of dioleoylphosphatidylethanolamine vesicles triggered by cleavage of surface-grafted poly(ethylene glycol) FEBS Lett. 388, 115-118 10.1016/0014-5793(96)00521-2
123. Ishida, T., Kirchmeier, M. J., Moase, E. H., Zalipsky, S., and Allen, T. M. (2001) Targeted delivery and triggered release of liposomal doxorubicin enhances cytotoxicity against human B lymphoma cells Biochim. Biophys. Acta, Biomembr. 1515, 144-158 10.1016/S0005-2736(01)00409-6
124. Mura, S., Nicolas, J., and Couvreur, P. (2013) Stimuli-responsive nanocarriers for drug delivery Nat. Mater. 12, 991-1003 10.1038/nmat3776